A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF less than 35 percent) and Mild to Moderate Heart Failure
Latest Information Update: 24 Dec 2020
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart failure; Left ventricular dysfunction
- Focus Pharmacodynamics
- Acronyms REMODEL
- Sponsors Pfizer
- 18 Mar 2010 Results published in Circulation.
- 01 Sep 2006 Status change
- 19 Oct 2005 New trial record.